Aloha Vision Consultants
‘Aiea, Hawaii, 96701, United States
Location status: Recruiting
Recruiting
NCT Number: NCT07176416
Effective Phaco Time and Endothelial Cell Loss When Using Veritas
This study is a single center, prospective study of cumulative dissipated energy and endothelial cells loss per phacoemulsification procedure after successful cataract surgery. Subjects will be assessed 3 months postoperatively at a single visit. Clinical evaluations will include central corneal thickness, specular microscopy, as well as measurement of visual acuities at distance.
Recruiting
Interested in participating?
Request InfoKey information
Conditions
Sex eligibility
All sexes
Study type
Observational
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Adult patients undergoing age-related cataract surgery.
- Planned use of the Catalys Precision Laser System.
- Planned implantation of TECNIS intraocular lenses (IOLs).
Exclusion criteria
- Moderate-severe any disease state (deemed by the surgeon) that could increase risk of complicated cataract surgery (ie, pseudoexfoliation syndrome, zonular dehiscence, history of eye trauma, and prior refractive surgery).
Treatment and study plan
Veritas Vision System
DeviceVeritas Vision System
Primary outcomes
-
Effective phaco time per phacoemulsification procedure
Time frame: Surgery (Day 0)
Secondary outcomes
-
Endothelial cell loss
Time frame: 1 monthspostoperatively
-
Total case time
Time frame: Surgery (Day 0)
total case time per procedure
-
Total phaco time
Time frame: Surgery (Day 0)
total phaco time per procedure
-
Total volume used
Time frame: Surgery (Day 0)
Total volume used per procedure
Study contacts
Contact information is provided by the study sponsor or research team.
Sponsors and collaborators
Lead sponsor
Aloha Vision Consultants
Other
Collaborators
- Sengi
Registry information
Official study title
Assessment of Effective Phaco Time and Endothelial Cell Loss When Using a Novel Dual Mode Phacoemulsification System
Important dates
- Study start
- 2025
- Primary completion
- 2026
- Study completion
- 2026
- First posted
- Sep 16, 2025
- Registry last updated
- Oct 9, 2025
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Recruiting
JASPER™ Robotic Surgical System (Formerly Known as the ORYOM™ Robotic Surgical System) in Cataract Surgery
NCT07468409
Cataract, Eye Diseases
Makati City, National Capital Region, Philippines
View Trial Details
Recruiting
Post-refractive IOL Outcomes With Clareon TruPlus
NCT07610226
Cataract, Eye Diseases
Greensboro, North Carolina, United States
View Trial Details
Recruiting
Randomized Controlled Trial of the STEIN Protocol: A Neuroplastic Pain Education and Guided Breathing Intervention During Awake Cataract Surgery
NCT07715591
Anxiety Disorders, Behavior
Los Angeles, California, United States
View Trial Details
Recruiting
Toric Performance And Constant Evaluation
NCT07471295
Cataract, Eye Diseases
Prague, Czechia
View Trial Details